Sedlákova I, Vávrová J, Tosner J, Hanousek L
Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.
Ceska Gynekol. 2006 Jul;71(4):312-7.
To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women without ovarian pathology.
Prospective study.
Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.
The method for LPA level analyze with its specification by capillary electrophoresis using indirect ultraviolet detection has been implementated. Since the beginning of this project venous blood samples from 103 patients (60 patients with ovarian cancer, 43 patients without ovarian pathology) have been obtained.
Plasma LPA levels were elevated in ovarian cancer patients (sigma LPA Med 19.9 micromol/l, Range 4.5-42.7 micromol/l). Patients without ovarian pathology (n=35) (sigma LPA Med 2.6 micromol/l, Range 0.9-22.9 micromol/l, P<0,001) had statistically significant lower plasma LPA level compared with ovarian cancer patients.
Lysophosphatidic acid appears useful as diagnostic marker of ovarian cancer.
比较卵巢癌患者与无卵巢病变女性的血浆溶血磷脂酸（LPA）水平。
前瞻性研究。
赫拉德茨克拉洛韦大学医院妇产科。
采用间接紫外检测的毛细管电泳法对LPA水平进行分析及其标准化。自本项目启动以来，已采集了103例患者（60例卵巢癌患者，43例无卵巢病变患者）的静脉血样本。
卵巢癌患者的血浆LPA水平升高（LPA中位数为19.9微摩尔/升，范围为4.5 - 42.7微摩尔/升）。无卵巢病变的患者（n = 35）（LPA中位数为2.6微摩尔/升，范围为0.9 - 22.9微摩尔/升，P < 0.001）与卵巢癌患者相比，血浆LPA水平在统计学上显著较低。
溶血磷脂酸似乎可作为卵巢癌的诊断标志物。
